SIWA Therapeutics

About:

SIWA Therapeutics is a biotechnology company that has a monoclonal antibody that targets and destroys senescent cells.

Website: http://www.siwatherapeutics.com/home

Twitter/X: siwathera

Description:

They founded SIWA in 2006 to develop biological therapies, including their proprietary humanized monoclonal antibody, SIWA 318H, for slowing or reversing the aging process through the removal of SCs. SCs are causally implicated in age-related dysfunction and in degenerative disease. These cells act primarily by secreting substances which interfere with normal functions of other cells; thus, removing them has been shown to improve healthspan and lifespan.

Total Funding Amount:

$1.63M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Chicago, Illinois, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)siwatherapeutics.com

Founders:

Lewis S. Gruber, Misty Gruber

Number of Employees:

1-10

Last Funding Date:

2017-05-22

IPO Status:

Private

Industries:

© 2025 bioDAO.ai